Hologic today launched Ultimate Defense, a nationwide initiative designed to increase adherence to routine Pap and HPV screening guidelines among U.S. women. The campaign will deploy targeted outreach across 20 states, partnering with over 150 women’s health clinics and community health centers. Hologic aims to address a troubling trend: while clinical guidelines recommend screening every three years, recent data from the Centers for Disease Control and Prevention indicate nearly 18% of women aged 21–65 have not been screened within the past five years. Ultimate Defense will feature educational webinars for clinicians, digital reminder tools for patients and subsidized test kits for low-income communities, with an initial goal of boosting screening rates by 10 percentage points within the first 12 months.

Hologic announced it will release its first quarter fiscal 2026 financial results on Thursday, January 29, 2026, following market close. In light of the company’s pending acquisition by Blackstone and TPG, Hologic confirmed there will be no live conference call or forward-looking financial guidance for the quarter ending December 31, 2025. This decision follows similar measures taken in prior quarters when strategic transactions were in progress. Hologic continues to focus on its core women’s health businesses—molecular diagnostics, biopsy systems and imaging platforms—which collectively accounted for more than 65% of total revenue in fiscal 2025.